Mustang Bio Reports Exit/Disposal Costs

Ticker: MBIO · Form: 8-K · Filed: Apr 12, 2024 · CIK: 1680048

Sentiment: neutral

Topics: restructuring, disposal, corporate-action

TL;DR

Mustang Bio is shedding some assets/operations, details to follow.

AI Summary

Mustang Bio, Inc. filed an 8-K on April 12, 2024, reporting costs associated with exit or disposal activities as of April 10, 2024. The filing does not specify the exact dollar amounts or nature of these costs, but indicates a formal reporting of such activities.

Why It Matters

This filing signals potential restructuring or divestment activities within Mustang Bio, which could impact its future operations and financial standing.

Risk Assessment

Risk Level: medium — Reporting exit or disposal costs can indicate financial distress or strategic shifts that carry inherent business risks.

Key Players & Entities

FAQ

What specific activities are associated with the reported exit or disposal costs?

The filing does not specify the exact nature of the exit or disposal activities, only that costs are associated with them.

When were these exit or disposal activities initiated or recognized?

The filing states the date as of which these costs are reported is April 10, 2024.

What is the total dollar amount of the costs associated with exit or disposal activities?

The filing does not disclose the specific dollar amount of these costs.

Is this filing related to a specific business segment or product line being divested?

The filing does not provide details on which specific segments or products are affected by the exit or disposal activities.

What is the purpose of reporting these costs on an 8-K form?

An 8-K is used to report material events that are of interest to shareholders and the public, including significant costs associated with exiting or disposing of business activities.

Filing Stats: 1,068 words · 4 min read · ~4 pages · Grade level 16 · Accepted 2024-04-12 16:15:20

Key Financial Figures

Filing Documents

05. Costs Associated with Exit or Disposal Activities

Item 2.05. Costs Associated with Exit or Disposal Activities. On April 10, 2024, the board of directors of Mustang Bio, Inc. ("Mustang") approved a reduction of its workforce by approximately 81% of its employee base in order to reduce costs and preserve capital due to the fundraising environment and continued uncertainty regarding the U.S. Committee on Foreign Investment in the United States ("CFIUS") review of the sale of the Company's leasehold interest in its cell processing facility located in Worcester, Massachusetts (the "Facility") and associated assets relating to the manufacturing and production of cell and gene therapies at the Facility (the "Transaction") to uBriGene (Boston) Biosciences, Inc., a Delaware corporation ("uBriGene") and an indirect, wholly owned subsidiary of UBriGene (Jiangsu) Biosciences Co., Ltd., a Chinese contract development and manufacturing organization. The workforce reduction will take place primarily in April 2024 and is expected to be substantially completed in the second quarter of 2024. As a result of these actions, Mustang expects to incur personnel-related restructuring charges of approximately $0.2 million in connection with one-time employee termination cash expenditures, which are expected to be incurred in the second quarter of 2024. Mustang may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction or retention efforts. The estimates of the Mustang costs expected to be incurred, and the timing thereof, are subject to various assumptions and actual costs may differ. The Company and its board of directors continue to evaluate all strategic and other alternatives related to the business.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements, include, but are not limited to, any statements relating to our workforce reduction and other alternatives, growth strategy and product development programs, including the timing of and our ability to make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates and any other statements that are not historical facts. Actual events or results may differ materially from those described herein due to a number of risks and uncertainties. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions necessary to transfer the lease of Mustang's manufacturing facility and receive the contingent payment in connection with Mustang's sale of its manufacturing facility in the anticipated timeframe or at all; whether the purchaser of Mustang's manufacturing facility is able to successfully perform its obligation to produce Mustang's products under the manufacturing services agreement on a timely basis and to acceptable standards; disruption from the sale of Mustang's manufacturing facility making it more difficult to maintain business and operational relationships; negative effects of the announcement or the consummation of the transaction on the market price of Mustang's common stock; significant transaction costs; the development stage of Mustang's primary product candidates, our ability t

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mustang Bio, Inc. Date: April 12, 2024 By: /s/ Manuel Litchman, M.D. Manuel Litchman, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing